Related Experiment Video
Updated: Jul 19, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Using ACE inhibitors appropriately
1Family Practice Residency Program, University of Pittsburgh Medical Center-McKeesport, Pennsylvania 15132, USA. bicketdp@msx.upmc.edu
Insights
Angiotensin-converting enzyme (ACE) inhibitors, initially for hypertension, now treat heart failure, diabetes, and kidney disease by blocking the renin-angiotensin-aldosterone system. These drugs reduce cardiovascular events and are well-tolerated.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Angiotensin-converting enzyme (ACE) inhibitors were first approved for hypertension in 1981.
- Their therapeutic applications have since expanded significantly due to their impact on the renin-angiotensin-aldosterone system.
Purpose of the Study:
- To review the expanded indications and clinical outcomes of ACE inhibitors.
- To highlight their role in managing cardiovascular and renal diseases.
Main Methods:
- Review of clinical outcomes and established indications for ACE inhibitors.
- Analysis of the pathophysiological mechanisms targeted by ACE inhibitors.
Main Results:
- ACE inhibitors reduce morbidity and mortality in conditions including congestive heart failure, myocardial infarction, diabetes, and chronic renal insufficiency.
- They attenuate the effects of Angiotensin II, such as endothelial dysfunction, altered renal hemodynamics, and cardiac hypertrophy.
- Clinical outcomes include reduced rates of myocardial infarction, stroke, end-stage renal disease, and heart failure mortality.
Conclusions:
- ACE inhibitors are effective in a wide range of cardiovascular and renal conditions.
- They offer significant benefits by mitigating the detrimental effects of the renin-angiotensin-aldosterone system.
- ACE inhibitors are generally well-tolerated with a favorable safety profile.
Abstract:
When first introduced in 1981, angiotensin-converting enzyme (ACE) inhibitors were indicated only for treatment of refractory hypertension. Since then, they have been shown to reduce morbidity or mortality in congestive heart failure, myocardial infarction, diabetes mellitus, chronic renal insufficiency, and atherosclerotic cardiovascular disease. Pathologies underlying these conditions are, in part, attributable to the renin-angiotensin-aldosterone system. Angiotensin II contributes to endothelial dysfunction. altered renal hemodynamics, and vascular and cardiac hypertrophy. ACE inhibitors attenuate these effects. Clinical outcomes of ACE inhibition include decreases in myocardial infarction (fatal and nonfatal), reinfarction, angina, stroke, end-stage renal disease, and morbidity and mortality associated with heart failure. ACE inhibitors are generally well tolerated and have few contraindications. (Am Fam Physician 2002;66:473.)
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Hypertension IV: Drug Therapy and Lifestyle Modifications

